Which patients with mild cognitive impairment do you consider referring for amyloid-targeted therapy?

This is an important question, as clearly, not everyone with MCI is appropriate or interested in Amyloid-Targeted Therapy. In general, I would say that the TrailBlazer trial did not change my approach to patient selection much, but it did provide more evidence that this class of drugs have a place i...